natgillin/translations-raw huggingface dataset:
The lack of experience in patients with HIV infection or active hepatitis, with severe immunological diseases (e.g. multiple sclerosis, lupus erythematosus, multifocal leukoencephalopathy) or treated with immunosuppressive therapy (other than short-term systemic corticosteroids) and that Daliresp should not be initiated or should be stopped in these patients.
Pomanjkanje izkušenj pri bolnikih z okužbo HIV ali aktivnim hepatitisom, z resnimi imunološkimi boleznimi (npr. multiplo sklerozo, eritematoznim lupusom, multifokalno leukoencefalopatijo) ali na zdravljenju z imunosupresivnimi zdravili (razen kratkotrajnega zdravljenja s sistemskimi kortikosteroidi) in zdravila Daliresp se pri teh bolnikih ne sme uvajati oz. ga je treba ukiniti.
The lack of experience in patients with HIV infection or active hepatitis, with severe immunological diseases (e.g. multiple sclerosis, lupus erythematosus, multifocal leukoencephalopathy) or treated with immunosuppressive therapy (other than short-term systemic corticosteroids) and that Daxas should not be initiated or should be stopped in these patients.
Pomanjkanje izkušenj pri bolnikih z okužbo HIV ali aktivnim hepatitisom, z resnimi imunološkimi boleznimi (npr. multiplo sklerozo, eritematoznim lupusom, multifokalno leukoencefalopatijo) ali na zdravljenju z imunosupresivnimi zdravili (razen kratkotrajnega zdravljenja s sistemskimi kortikosteroidi) in zdravila Daxas se pri teh bolnikih ne sme uvajati oz. ga je treba ukiniti.
The lack of experience in patients with HIV infection or active hepatitis, with severe immunological diseases (e.g..multiple sclerosis, lupus erythematosus, multifocal leukoencephalopathy) or treated with immunosuppressive therapy (other than short-term systemic corticosteroids) and that Libertek should not be initiated or should be stopped in these patients.
Pomanjkanje izkušenj pri bolnikih z okužbo HIV ali aktivnim hepatitisom, z resnimi imunološkimi boleznimi (npr. multiplo sklerozo, eritematoznim lupusom, multifokalno leukoencefalopatijo) ali na zdravljenju z imunosupresivnimi zdravili (razen kratkotrajnega zdravljenja s sistemskimi kortikosteroidi) in zdravila Libertek se pri teh bolnikih ne sme uvajati oz. ga je treba ukiniti.
The Lantus cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Lantus se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Lantus cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Lantus se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Lantus cartridges should only be used with the following pens:
Vložki zdravila Lantus se lahko uporabljajo samo z naslednjimi injekcijskimi peresniki:
The larger the dose, the longer it will take to inject.
Večji kot je odmerek, dlje traja injiciranje.
The largest of these trials (n= 277) enrolled patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as visual analog scale (VAS) scores of  30 for average of duration and intensity of morning stiffness plus VAS scores of  30 for at least 2 of the following 3 parameters: patient global assessment; average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the Bath Ankylosing Spondylitis Functional Index (BASFI).
Največje od teh preskušanj (n = 277) je vključevalo bolnike med 18. in 70. letom starosti z aktivnim ankilozirajočim spondilitisom, definiranim po vizualni analogni lestvici (VAS) z vrednostjo ≥ 30 za povprečno trajanje in intenzivnost jutranje okorelosti ter VAS vrednost ≥ 30 za vsaj 2 od 3 sledečih parametrov: bolnikova splošna ocena; povprečna VAS vrednost bolečine v hrbtenici ponoči in celokupne bolečine v hrbtenici; povprečje 10 vprašanj v Bath Ankylosing Spondylitis Functional Index (BASFI).
The largest reactions were seen around 7 days post administration when the maximum size was 13 x 7 cm.
Največje reakcije so bile vidne 7 dni po dajanju, ko je bila največja velikost 13 x 7 cm.
The largest study IMP24011 (n=793) included patients (n=526) who were not controlled by, contraindicated to, or intolerant to two or more systemic therapies as judged from the patients’ histories of psoriasis treatment.
Največja študija IMP24011 (n=793) je vključevala bolnike (n=526), ki niso bili pod nadzorom z, niso imeli kontraindikacij za ali niso prenašali dveh ali več sistemskih zdravil, po presoji podatkov o bolnikovem zdravljenju psoriaze v preteklosti.
The largest study of Orfadin was carried out in 257 patients in 87 different hospitals in 25 countries, as part of a ‘compassionate-use’ programme.
V največji študiji zdravila Orfadin je sodelovalo 257 bolnikov v 87 različnih bolnišnicah v 25 državah kot del programa „sočutne uporabe“.
The laser light application will induce difficulties with swallowing (pain, nausea and vomiting).
Uporaba laserske svetlobe povzroči težave pri požiranju (bolečino, slabost in bruhanje).
The last thick line visible on the injection button shows the amount of insulin loaded.
Zadnja vidna debela črta na gumbu za injiciranje kaže napolnjeni odmerek insulina.
The latter appears to be related to thalidomide and occurred at exposures greater than 2.4 fold the human exposure.
Kaže, da je slednje povezano s talidomidom in se pojavi pri izpostavljenostih, ki so 2,4-krat višje od izpostavljenosti pri ljudeh.
The latter contained 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface antigen.
Slednje je vsebovalo 360 ELISA enot s formalinom inaktiviranega virusa hepatitisa A in
The latter finding was not observed in pigmented rats, nor in a 2-year albino mouse carcinogenicity study or in any other species investigated.
Zadnje ugotovitve niso opazili niti pri pigmentiranih podganah niti v raziskavi kancerogenosti pri 2- letnih albino miših ali katerikoli drugi raziskovani vrsti.
The LDLR also binds triglyceride-rich VLDL remnant lipoproteins and intermediate-density lipoprotein (IDL).
LDLR vežejo tudi s trigliceridi bogate preostale VLDL-lipoproteine in lipoproteine srednje gostote (IDL – intermediate-density lipoprotein).
The lead-in period is not required if the patient is already on chronic Viramune 200 mg tablets or Viramune oral suspension twice daily treatment.
Uvajalno obdobje ni potrebno, če se bolnik že zdravi z zdravilom Viramune 200 mg tablete ali zdravilom Viramune 50 mg/5ml peroralna suspenzija, ki ju jemlje dvakrat dnevno.
The leaflet was approved in
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}>
The length of combination antiretroviral therapy, use of corticosteroids, alcohol consumption, severe immunosuppression, higher body mass index, among other factors, may increase the risk of developing this disease.
Dolžina trajanja kombiniranega protiretrovirusnega zdravljenja, uporaba kortikosteroidov, uživanje alkohola, hudo zavrtje imunskega sistema, višji indeks telesne mase, poleg ostalih dejavnikov, lahko zvišajo tveganje za razvoj te bolezni.
The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm.
Dolžina kapsule znaša od 19,1 mm do 19,7 mm in je široka 6,91 mm.
The length of time that Circovac is effective in the piglets has also been studied.
Preučevali so tudi trajanje učinka cepiva Circovac pri pujskih.
The length of treatment depends on where the infection is, how severe it is, and the patient’s response to treatment.
Trajanje zdravljenja je odvisno od mesta okužbe, resnosti okužbe ter od bolnikovega odziva na zdravljenje.
The lethal dose of acetylsalicylic acid is 25-30 g.
Smrtni odmerek acetilsalicilne kisline je od 25 do 30 g.
The letters "S", "M" and "L" refer to the different strengths of tablets: "
Črke "S", "M" in "L" označujejo različne jakosti tablet: "
The leukapheresis process
Postopek levkafereze
The level of activity in the bone was in the range of 44% to 77% at 4 hours post injection.
Raven aktivnosti v kosteh je bila 4 ure po injiciranju v razponu od 44 % do 77 %.
The level of digoxin or digitoxin in your blood may need to be checked if taken with Invokana. dabigatran (blood thinner medicine that lowers the risk of blood clot formation).
Če v času zdravljenja z zdravilom Invokana jemljete digoksin oziroma digitoksin, bo treba izmeriti njuni koncentraciji v krvi. dabigatran (zdravilo za redčenje krvi, ki zmanjšuje nastajanje krvnih strdkov)
The levels of the medicine in the body reach a steady level within a month of starting treatment.
Raven zdravila v telesu se ustali v enem mesecu po začetku zdravljenja.
The levels of these antibodies decline with time but are still high enough to be reliably effective four to six weeks after the second injection.
Ravni teh protiteles se sčasoma nižajo, vendar so še vedno dovolj visoke, da so učinkovite štiri do šest tednov po drugi injekciji.
The light blue cap is imprinted with Raptor logo in white ink and the light blue body is imprinted with “25 mg” in white ink.
Na svetlomodrem pokrovčku je z belim črnilom odtisnjen logotip družbe Raptor, na svetlomodrem osrednjem delu pa je odtisnjena bela oznaka „25 mg‟.
The light dose administered will be 130 Joules/cm (J/cm) of diffuser length using a centring balloon.
Uporabljeni odmerek svetlobe je 130 joulov/cm (J/cm) dolžine difuzorja z uporabo balona za centriranje.
The light will turn from green to flashing orange slowly indicating that injection has begun.
Lučka se bo počasi spreminjala z zelene na utripajočo oranžno, kar označuje, da se je injiciranje začelo.
The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance.
Zaradi omejene presnove in vezave na beljakovine v plazmi ter skoraj popolnega izločanja nespremenjene učinkovine skozi ledvice je verjetnost presnovnih interakcij majhna.
The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10 %) extent of hepatic metabolism and the low plasma protein binding.
Zaradi majhnega (5 do 10 %) obsega jetrne presnove in majhne vezave na plazemske proteine je verjetnost interakcij presnovnih substanc z lamivudinom majhna.
The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10 %) extent of hepatic metabolism and the low plasma protein binding.
Zaradi majhnega obsega jetrne presnove (5 do 10 %) in majhne vezave na beljakovine v plazmi je verjetnost interakcij presnovnih substanc z lamivudinom majhna.
The limbus is part of the eye.
Limbus ali roženični rob je del očesa.
The limitation of the total area than can be treated to 15% TBSA
Omejitev skupne površine, ki jo je dovoljeno zdraviti, je 15 % CPT
The limited data available do not suggest any major differences in the blood cell production of patients receiving chemotherapy after treatment with Xofigo compared with those who did not receive Xofigo.
Omejeni podatki ne kažejo velikih razlik v nastajanju krvnih celic pri bolnikih, ki prejemajo kemoterapijo po zdravljenju z zdravilom Xofigo v primerjavi z bolniki, ki se niso zdravili z zdravilom Xofigo.
The limited data available from a phase IIa study in HIV-infected patients have shown a clinically non significant 20 % decrease of TPV Cmin.
Omejeni podatki iz raziskave faze IIa pri bolnikih okuženih s HIV kažejo na klinično nepomembno 20-odstotno zmanjšanje Cmin TPV.
The limited data available from a phase IIa study in HIV-infected patients have shown a clinically non significant 20% decrease of TPV Cmin.
Omejeni podatki iz raziskave faze IIa pri bolnikih okuženih s HIV kažejo na klinično nepomembno 20 % zmanjšanje Cmin TPV.
The limited data available with saquinavir soft gel capsule boosted with ritonavir do not suggest any clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine
Manjše število podatkov, ki so na voljo o uporabi mehkih želatinskih kapsul sakvinavirja ob sočasnem jemanju ritonavirja, ne kaže na klinično pomembno interakcijo med sakvinavirjem ob sočasnem jemanju ritonavirja in nevirapina.
The limited data available with saquinavir soft gel capsule boosted with ritonavir do not suggest any clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine
Omejeno število podatkov, ki so na voljo o uporabi mehkih želatinskih kapsul sakvinavirja ob sočasnem jemanju ritonavirja, ne kaže na klinično pomembno interakcijo med sakvinavirjem ob sočasnem jemanju ritonavirja in nevirapina.
The limited data available with saquinavir soft gel capsule boosted with ritonavir do not suggest any clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine.
Manjše število podatkov, ki so na voljo o uporabi mehkih želatinskih kapsul sakvinavirja ob sočasnem jemanju ritonavirja, ne kaže na klinično pomembno interakcijo med
The limited data available with saquinavir soft gel capsule boosted with ritonavir do not suggest any clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine.
Manjše število podatkov, ki so na voljo o uporabi mehkih želatinskih kapsul sakvinavirja ob sočasnem jemanju ritonavirja, ne kaže na klinično pomembno interakcijo med sakvinavirjem ob sočasnem jemanju ritonavirja in nevirapina.
The limited data for these somatic tumour BRCA (sBRCA) mutated patients show that fewer patients on olaparib reported progression events or death events compared with placebo (Table 3).
Maloštevilni podatki o bolnicah s temi somatskimi tumorskimi mutacijami gena BRCA (sBRCA) kažejo, da je bilo dogodkov napredovanja ali smrti med prejemnicami olapariba manj kot med prejemnicami placeba (preglednica 3).
The limited data from animal studies do not indicate direct reproductive toxicity (see section 5.3).
Omejeni podatki iz študij na živalih niso pokazali neposrednega vpliva na sposobnost razmnoževanja (glejte poglavje 5.3).
The limited data from the present trial preclude any conclusions regarding the efficacy of subsequent courses of MabThera in patients with granulomatosis with polyangiitis and microscopic polyangiitis.
Ker je podatkov iz tega preskušanja malo, ni mogoče sklepati o učinkovitosti nadaljnjih ciklov zdravila MabThera pri bolnikih z granulomatozo s poliangiitisom in z mikroskopskim poliangiitisom.
The lincosamides (clindamycin, lincomycin, and pirlimycin) inhibit protein synthesis in Gram-positive and in anaerobic bacteria as well as in Mycoplasma spp.
Linkozamidi (klindamicin, linkomicin in pirlimicin) inhibirajo sintezo beljakovin pri grampozitivnih in anaerobnih bakterijah kot tudi pri Mycoplasmi spp.
The line with sodium chloride 9 mg/mL (0.9 %) solution for injection should be flushed at the end of the infusion.
Po infuziji je treba linijo sprati z 0,9-odstotno raztopino natrijevega klorida za injiciranje.
The linear clearance estimated as a parameter in the population pharmacokinetic analysis was 0.146 ml/hr/kg.
Linearni očistek, parameter v analizi populacijske farmakokinetike, je bil 0,146 ml/h/kg.
The linear clearance estimated as a parameter in the population pharmacokinetic analysis, was 0.142 ml/hr/kg.
Linearni očistek, parameter v analizi populacijske farmakokinetike, je bil 0,142 ml/h/kg.
The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 9.5 ml/h.
Linearni očistek so ocenili kot parameter v analizi populacijske farmakokinetike, znašal je 9,5 ml/h.
The lipid-lowering properties of fenofibrate seen in clinical practice have been explained in vivo in transgenic mice and in human hepatocyte cultures by activation of Peroxisome Proliferator Activated Receptor type α (PPARα).
Lastnost fenofibrata, da znižuje koncentracijo lipidov, ki je bila opažena v klinični praksi, je bila pojasnjena in vivo pri transgenskih miših in s kulturami humanih hepatocitov z aktivacijo s peroksisomskim proliferatorjem aktiviranega receptorja α (PPARα).
The liposomal suspension is infused intravenously over about one hour.
Intravensko infundiranje liposomske suspenzije traja približno eno uro.
The Liprolog Basal in your KwikPen is the same as the Liprolog Basal, which comes in separate Liprolog Basal cartridges.
Zdravilo Liprolog Basal v vašem KwikPenu je enako zdravilu Liprolog Basal, ki se dobavlja v posameznih vložkih zdravila Liprolog Basal.
The Liprolog Basal KwikPen comes in a pack of 5 pre-filled pens or a multipack of 2 x 5 pre-filled pens.
Liprolog Basal KwikPen je na voljo v pakiranju po 5 injekcijskih peresnikov ali kot večje pakiranje 2 x 5 injekcijskih peresnikov.
The Liprolog KwikPen comes in a pack of 5 pre- filled pens or a multipack of 2 x 5 pre-filled pens.
Injekcijski peresniki zdravila Liprolog KwikPen so na voljo v pakiranju po 5 injekcijskih peresnikov ali kot večje pakiranje 2 x 5 injekcijskih peresnikov.
The Liprolog solution should be clear and colourless.
Raztopina zdravila Liprolog mora biti bistra in brezbarvna.
The liquid comes in a pre-filled syringe labeled ‘Solvent for SOMAVERT’.
Tekočina je na voljo v napolnjeni injekcijski brizgi z oznako 'Vehikel za zdravilo SOMAVERT'.
The liquid contains a protein of feline leukaemia virus (FeLV).
Tekočina vsebuje beljakovino virusa mačje levkemije (FeLV).
The liquid diphtheria, tetanus, pertussis (whole cell), hepatitis B (DTPw-HBV) component is a turbid white suspension.
Komponente cepiva proti davici (D), tetanusu (T), oslovskemu kašlju (celotna celica; Pw) in hepatitisu B (HBV) (DTPw-HBV) so v tekočem stanju in sicer v obliki motne bele suspenzije.
The liquid in the medication window must be clear and colourless.
Tekočina v okencu za zdravilo mora biti bistra in brezbarvna.
the liquid is coloured or you can see particles floating in it
če je tekočina obarvana ali če je videti v njej plavati delce
the liquid is coloured or you can see particles floating in it, the seal is broken.
da je tekočina obarvana ali v njej vidite plavati delce, da je tesnilo poškodovano.
The liquid is coloured or you can see particles floating in it.
če je tekočina obarvana ali če je videti v njej plavati delce
The liquid may look cloudy - this is okay.
Tekočina je morda videti motna – to je v redu.
The liquid should be clear to pale yellow.
Raztopina mora biti bistra do bledo rumena.
The liquid should look cloudy.
Tekočina mora biti motna.
The liquid will have a yellow colour and there will be large air bubbles on top of the liquid.
Tekočina bo rumene barve in na vrhu tekočine bodo veliki mehurčki.
The list below also provides information on the adverse reactions of the individual components naltrexone (N) and bupropion (B) identified in the respective approved SmPCs.
Na spodnjem seznamu so navedeni tudi podatki o neželenih učinkih za posamezni sestavini, naltrekson (N) in bupropion (B), identificiranih v zadevnih odobrenih povzetkih glavnih značilnosti zdravila.
The list below contains adverse reactions seen in clinical trials or that were spontaneously reported, classified by system organ class and frequency.
V spodnjem seznamu so navedeni neželeni učinki, zabeleženi v kliničnih preskušanjih, ali neželeni učinki, o katerih so poročali spontano; razvrščeni so po skupinah organskih sistemov in pogostnosti pojavljanja.
The list below includes adverse reactions which were reported with a higher incidence in placebo- controlled studies in patients receiving 1 mg/day rasagiline (rasagiline group n=380, placebo group n=388).
Spodnji seznam vključuje neželene učinke, ki so bili sporočani z večjo incidenco v s placebom kontroliranih študijah pri bolnikih, ki so prejemali razagilin 1 mg/dan (skupina razagilina n = 380, skupina placeba n = 388).
The list below includes adverse reactions which were reported with a higher incidence in placebo- controlled studies, in patients receiving 1 mg/day rasagiline (rasagiline group n=149, placebo group n=151).
Spodnji seznam vključuje neželene učinke, ki so bili z večjo incidenco sporočani v s placebom kontroliranih študijah pri bolnikih, ki so prejemali razagilin 1 mg/dan (skupina razagilina n = 149, skupina placeba n = 151).
The list of bacteria against which Doribax is active can be found in the summary of product characteristics (also part of the EPAR).
Seznam bakterij, proti katerim je zdravilo Doribax učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
The list of bacteria against which Invanz is active can be found in the summary of product characteristics (also part of the EPAR).
Za seznam bakterij, proti katerim zdravilo Invanz učinkuje, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
The list of fungi against which Voriconazole Hospira is active can be found in the summary of product characteristics (also part of the EPAR).
Seznam glivic, proti katerim učinkuje zdravilo Voriconazole Hospira, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
The listed interactions apply both to adults and children.
Našteta opozorila in previdnostni ukrepi veljajo tako za odrasle kot za otroke.
The listed warnings and precautions apply both to adults and children.
Navedena opozorila in previdnostni ukrepi veljajo za odrasle bolnike in otroke.
The listed warnings and precautions apply both to adults and children.
Našteta opozorila in varnostni ukrepi veljajo za odrasle in otroke.
The listed warnings and precautions apply to adults, children and adolescents.
Našteta opozorila in previdnostni ukrepi veljajo za odrasle, otroke in mladostnike.
The listed warnings and precautions apply to both adults and children (from 0 to 18 years of age).
Navedena opozorila in previdnostni ukrepi veljajo za odrasle in otroke (stare med 0 in 18 let).
The listed warnings and precautions apply to both adults and children.
Navedena opozorila in previdnostni ukrepi veljajo za odrasle in otroke.
The listed warnings and precautions apply to patients of all ages, adults and children.
Navedena opozorila in previdnostni ukrepi veljajo za bolnike vseh starosti, za odrasle in otroke.
The listed warnings and precautions apply to patients of all ages, adults and children.
Navedena opozorila n previdnostni ukrepi se nanašajo na bolnike vseh starosti, odrasle in otroke.
The listed warnings and precautions apply to patients of all ages, adults and children.
Navedena opozorila n previdnostni ukrepi veljajo za bolnike vseh starosti, odrasle in otroke.
The listing also takes into account serious adverse reactions and adverse reactions leading to discontinuation reported in three clinical long-term studies including 21,642 patients treated with telmisartan for the reduction of cardiovascular morbidity for up to six years.
Seznam upošteva tudi resne neželene učinke in neželene učinke, ki so povzročili prekinitev zdravljenja, zabeležene v treh dolgoročnih kliničnih študijah, ki so zajele 21642 bolnikov, do šest let zdravljenih s telmisartanom za zmanjšanje srčnožilne obolevnosti.
The literature on busulfan suggests a therapeutic AUC window between 900 and 1500 µmol/L.minute per administration (equivalent to a daily exposure between 3600 and 6000 µmol/L.minute).
Literatura o busulfanu priporoča terapevtsko AUC območje med 900 in 1.500 µmol/l·min, na uporabo (kar ustreza dnevni izpostavljenosti med 3.600 in 6.000 µmol/l. minuto).
The live attenuated virus vaccine strain CPiV may be shed by vaccinated animals following vaccination.
Cepljene živali lahko izločajo žive atenuirane vakcinalne seve CPiV.
The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated animals following vaccination, shedding of CPV has been shown for up to 10 days.
Cepljene živali lahko izločajo žive atenuirane vakcinalne seve CAV-2, CPiV in CPV, izločanje CPV so dokazali do 10 dni po cepljenju.
The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated animals following vaccination, shedding of CPV has been shown for up to 10 days.
Cepljene živali lahko izločajo žive atenuirane vakcinalne seve CAV-2, CPiV in CPV-2b, izločanje CPV so dokazali do 10 dni po cepljenju.